Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.74)
# 314
Out of 5,182 analysts
36
Total ratings
70.37%
Success rate
33.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $53 → $57 | $57.62 | -1.08% | 5 | Apr 29, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $17 → $21 | $13.09 | +60.43% | 5 | Apr 28, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $144 → $167 | $147.90 | +12.91% | 3 | Apr 14, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $44 → $48 | $28.90 | +66.09% | 2 | Apr 14, 2026 | |
| BCAX Bicara Therapeutics | Maintains: Equal-Weight | $11 → $16 | $22.72 | -29.58% | 4 | Mar 31, 2026 | |
| NUVL Nuvalent | Initiates: Overweight | $116 | $102.62 | +13.04% | 1 | Mar 30, 2026 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $8 → $27 | $38.39 | -29.67% | 1 | Mar 24, 2026 | |
| GMAB Genmab | Initiates: Overweight | $40 | $27.04 | +47.93% | 1 | Mar 2, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $30 → $23 | $26.05 | -11.71% | 5 | Feb 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $30 → $35 | $44.17 | -20.76% | 1 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $25 → $33 | $26.78 | +23.23% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $28.52 | +110.38% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $27 | $13.36 | +102.10% | 3 | Aug 7, 2025 |
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintains: Overweight
Price Target: $53 → $57
Current: $57.62
Upside: -1.08%
Relay Therapeutics
Apr 28, 2026
Maintains: Overweight
Price Target: $17 → $21
Current: $13.09
Upside: +60.43%
Revolution Medicines
Apr 14, 2026
Maintains: Overweight
Price Target: $144 → $167
Current: $147.90
Upside: +12.91%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Overweight
Price Target: $44 → $48
Current: $28.90
Upside: +66.09%
Bicara Therapeutics
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $22.72
Upside: -29.58%
Nuvalent
Mar 30, 2026
Initiates: Overweight
Price Target: $116
Current: $102.62
Upside: +13.04%
Sutro Biopharma
Mar 24, 2026
Upgrades: Overweight
Price Target: $8 → $27
Current: $38.39
Upside: -29.67%
Genmab
Mar 2, 2026
Initiates: Overweight
Price Target: $40
Current: $27.04
Upside: +47.93%
Arcus Biosciences
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $30 → $23
Current: $26.05
Upside: -11.71%
Exelixis
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $30 → $35
Current: $44.17
Upside: -20.76%
Dec 12, 2025
Upgrades: Overweight
Price Target: $25 → $33
Current: $26.78
Upside: +23.23%
Oct 31, 2025
Initiates: Overweight
Price Target: $60
Current: $28.52
Upside: +110.38%
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $13.36
Upside: +102.10%